Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 3
1987-09-01
To assess the effects of various postmenopausal estrogen replacement therapies on selected
cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood
pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in
collaboration with the National Institute of Child Health and Human Development, the National
Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of
Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended
follow-up is for 3 years focusing on endometrium and breast evaluation.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phase 3
1987-09-01
To assess the effects of various postmenopausal estrogen replacement therapies on selected
cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood
pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in
collaboration with the National Institute of Child Health and Human Development, the National
Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of
Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended
follow-up is for 3 years focusing on endometrium and breast evaluation.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3
1987-09-01
To assess the effects of various postmenopausal estrogen replacement therapies on selected
cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood
pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in
collaboration with the National Institute of Child Health and Human Development, the National
Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of
Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended
follow-up is for 3 years focusing on endometrium and breast evaluation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
